Early Stage Researchers
Matteo Guidetti
Solvias, Switzerland
SDU, Denmark
SDU, Denmark
Justus Lange
Roche, Switzerland
UCC,Ireland
UCC,Ireland
Nicolas Pätzmann
Zentiva, Czech Republic
ESR3
Computational tools to predict co-grinding approaches to overcome dissolution rate limited absorption
Profile
Lotte Ejskjær
UCC, Ireland
Shaida Panbachi
FHNW, Switzerland
Egis Zeneli
FHNW, Switzerland
Kristian Beran
Janssen, Belgium
ESR7
Comparison of rDCS to the pre-clinical suspension/solution approach for formulation selection
Profile
Laurin Zöller
AstraZeneca, Sweden
ESR8
Predicting the dissolution gains and precipitation risks of salt and co-crystal forms of drugs
Profile
Shirin Nika Dietrich
NKUA, Greece
ESR9
Development of an in vitro method for evaluating the impact of gastrointestinal (GI) transfer on performance
of enabling formulations under fed state conditions
Profile
Paul Vrenken
Bayer, Germany
ESR10
In silico methods for selecting oral formulations and dosing conditions in early clinical studies
Profile
Florentin Lukas Holzem
SDU, Denmark
ESR11
Integrating in vitro dissolution-permeation data with biopharmaceutical models to predict the in vivo performance of drug formulations
Profile
Malte Bøgh Senniksen
Fraunhofer, Germany
ESR12
Application of an end–to-end, animal-free modelling approach to the development of enabling drug products: focus on amorphous solid dispersions (ASD)
Profile
Felix Paulus
Janssen, Beligum
ESR13
Developing a novel two-stage in vitro lipolysis model to predict impact of digestion on drug absorption from supersaturating formulations
Profile